ARISING HEALTHALIVE. AWAKE. AWARE.Read the magazines →

← November 18, 2026 edited reader edition

THE ARISING · Longevity & Healthspan

A Blood Marker Helped Estimate Future Risk of Cognitive Impairment

A model put five- and ten-year numbers on risk. Whether using those numbers improves care remains untested.

Alzheimer's-related changes can appear years before symptoms, but a biomarker alone does not tell someone whether or when they will develop symptoms. Researchers asked whether a blood marker called p-tau217 could help estimate that risk when combined with age, sex and APOE ε4 status.

The analysis included 2,178 adults aged 60 to 90 from two research cohorts. All were cognitively unimpaired at the start. Higher p-tau217 was associated with a higher rate of progression to cognitive impairment.

In an illustrative example based on the Mayo Clinic cohort, the modeled five-year risk of mild cognitive impairment at age 75 was 7% at a p-tau217 concentration of 0.072 pg/mL and 17% at 0.324 pg/mL, holding sex and APOE ε4 at the cohort averages. The corresponding ten-year estimates were 15% and 35%. These are model estimates for a specified example, not screening cutoffs or predictions of what will happen to any one person.

One potential use is identifying people more likely to develop impairment when recruiting for prevention trials. The study did not test whether offering the blood test to people without symptoms improves decisions or outcomes. It used one laboratory platform, and the estimates need to be tested in broader populations. The FDA-cleared Lumipulse ratio test has a different purpose: it helps evaluate people with cognitive symptoms and is not intended for screening.

Risk estimation is also different from diagnosis. The researchers modeled whether people progressed from unimpaired cognition to mild cognitive impairment or dementia over time. These estimates are not probabilities that a person currently has Alzheimer's disease.

Primary study: JAMA Neurology · FDA device review

THE ARISING NEWSLETTER

Science moves forward.
Come with it.

Research, clear explanations, and a little room for wonder.
Read and follow The Arising on Substack.

Find The Arising on Substack ↗